Healthcare Technology Report April 29, 2024
Orthobond has achieved a significant milestone with FDA de novo approval for its Ostaguard antibacterial technology, marking the first time the FDA has granted such approval for a non-eluting coating designed to actively combat bacteria on medical devices. Developed by Orthobond, Ostaguard utilizes a proprietary quaternary ammonium compound coating to mechanically rupture the cell walls of bacteria, viruses, and fungi, thus reducing the risk of device-related infections during medical procedures.
Founded by Princeton University Chemistry...
Today's Sponsors
Today's Sponsor